Pancreatic Cancer Research

ResearcherUniversity of Electronic Science and Technology of ChinaActive in the last 2 years

Lulu Zhai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0839-7316; OpenAlex author ID A5048001151, A5159321956. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 5 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 15

  1. Metabolism pathway-based subtyping in pancreatic adenocarcinoma: an integrated study by bulk RNA-sequence and machine learning algorithms. Co-author DOI 10.1097/js9.0000000000005038↗
  2. Single-cell and bulk transcriptomics identify senescence-related EMT transcriptional programs and a prognostic framework in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12876-026-05043-6↗
  3. Curcumin inhibits the invasion and migration of pancreatic cancer cells by upregulating TFPI-2 to regulate ERK- and JNK-mediated epithelial-mesenchymal transit… Co-author DOI 10.1007/s00394-023-03296-5↗
  4. N6 -methyladenosine RNA demethylase FTO regulates extracellular matrix-related genes and promotes pancreatic cancer cell migration and invasion. Co-author DOI 10.1002/cam4.5054↗
  5. m6A RNA demethylase FTO promotes the growth, migration and invasion of pancreatic cancer cells through inhibiting TFPI-2. Co-author DOI 10.1080/15592294.2022.2061117↗
  6. Tumorigenic and immunological roles of Heat shock protein A2 in pancreatic cancer: a bioinformatics analysis. Co-author DOI 10.1590/1806-9282.20210495↗
  7. Nomogram for Predicting Distant Metastasis of Pancreatic Ductal Adenocarcinoma: A SEER-Based Population Study. Last author DOI 10.3390/curroncol29110643↗
  8. Long non‑coding RNA 01614 hyperactivates WNT/β‑catenin signaling to promote pancreatic cancer progression by suppressing GSK‑3β. Co-author DOI 10.3892/ijo.2022.5406↗
  9. Letter re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic… Co-author DOI 10.1016/j.ejca.2021.09.006↗
  10. Upregulated HSPA2 predicts early relapse of pancreatic cancer after surgery. Co-author DOI 10.21037/gs-21-262↗
  11. Upregulation of B3GNT3 Correlates With Poor Prognosis and Decreased Immune Cell Infiltration In Pancreatic Adenocarcinoma First author DOI 10.21203/rs.3.rs-218028/v1↗
  12. Panax notoginseng Saponins Promote Cell Death and Chemosensitivity in Pancreatic Cancer through the Apoptosis and Autophagy Pathways. Co-author DOI 10.2174/1871520620999201110191459↗
  13. Four potential microRNAs affect the progression of pancreatic ductal adenocarcinoma by targeting MET via the PI3K/AKT signaling pathway. Co-author DOI 10.3892/ol.2021.12588↗
  14. High-Level Expression and Prognostic Significance of Matrix Metalloprotease-19 and Matrix Metalloprotease-20 in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000569↗
  15. Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer. First author DOI 10.1016/j.ejso.2014.11.037↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lun Wu · 7 shared papers, 2021–2026 · strength 1.25
  2. Lichao Yao · 6 shared papers, 2021–2023 · strength 0.98
  3. Zhi‐Gang Tang · 5 shared papers, 2021–2022 · strength 0.89
  4. Tong-Fa Ju · 4 shared papers, 2021–2024 · strength 0.82
  5. Dalong Yin · 2 shared papers, 2024–2026 · strength 0.64
  6. Wei Wang · 3 shared papers, 2022–2024 · strength 0.62
  7. Long-Jiang Chen · 3 shared papers, 2022–2024 · strength 0.60
  8. Hao He · 1 shared paper, 2026 · strength 0.39
  9. Zhi‐Gang Tang · 2 shared papers, 2022–2023 · strength 0.36
  10. Zhi‐Gang Tang · 3 shared papers, 2016–2021 · strength 0.34
  11. Weibo Li · 2 shared papers, 2021–2022 · strength 0.34
  12. L Chen · 1 shared paper, 2026 · strength 0.30
  13. X Wang · 1 shared paper, 2026 · strength 0.30
  14. Xuan Pan · 1 shared paper, 2026 · strength 0.30
  15. Lin Ye · 2 shared papers, 2021 · strength 0.28
  16. Wei Wang · 1 shared paper, 2022 · strength 0.20
  17. Zhigang Tang · 1 shared paper, 2022 · strength 0.20
  18. Kaihuan Yu · 1 shared paper, 2023 · strength 0.19
  19. Jinzhuo Ning · 1 shared paper, 2022 · strength 0.16
  20. Chong-Yang Cai · 2 shared papers, 2015–2016 · strength 0.15
  21. Longjiang Chen · 1 shared paper, 2021 · strength 0.14
  22. Yang Feng Wu · 1 shared paper, 2016 · strength 0.08
  23. Qiang Huang · 1 shared paper, 2016 · strength 0.08
  24. Zige Tang · 1 shared paper, 2015 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.